Generating human induced pluripotent Stem Cell Banks.
Establishing well-characterized panels of iPSC lines that reflect the diversity of the human population and include samples from patients with a wide range of diseases will be key to tapping into the potential of iPSCs.
Experts in the field have published opinion pieces on emerging issues related to generating such iPSC banks, and they provide practical recommendations and creative solutions to address challenges associated with such large-scale efforts.
Expertise In Cell Culture
Dr. Glyn Stacey of the U.K.'s National Institute for Biological Standards and Control and his colleagues recommend approaches for using the knowledge of existing, well-established human embryonic stem cell banks and their experience in standardization to promote quality control in iPSC resource centers.
"Not all laboratories will have the same level of expertise in cell culture or familiarity with vital quality control procedures. These will be essential to avoid the circulation of iPSC lines that have become contaminated or switched with other cell lines," said Stacey. "Such events can lead to fundamental flaws in the published literature and a waste of precious research resources."
Cost-Effective Sharing Of Cell Lines
In another Forum, Dr. Mahendra Rao, director of the intramural Center for Regenerative Medicine at the National Institutes of Health, said that making iPSC lines and developing the requisite controls and tests is time consuming, expensive, and generally beyond the expertise of any single laboratory.
"Fulfilling the expectations for iPSCs and their use will only be possible if we develop a new cost-effective way to share and distribute cell lines. Crowd sourcing is one solution," he said.
For the model to be successful, it must be self-sustaining.
"Technology holders must buy in to the idea that it will ultimately benefit them as well as the users. It would also be important to ensure that expertise existed in the various repositories to store, characterize, test, and track the cells and their derivatives and that the repositories could do so at costs that were reasonable for the end user," Rao wrote.
The Importance Of Immune Matching
Lastly, Dr. Ian Wilmut and his colleagues address important considerations for immune matching between iPSC donors and recipients.
While it is possible that iPSC lines could be derived on an individual basis--so that an individual patient would receive his or her own cells as a treatment --it seems unlikely that this method would be used as a source for large numbers of patients in the near future due to time and cost restraints.
A more practical solution is to build a bank of stem cell lines from a small pool of individuals that match a majority of the patient population and could be safely transplanted without immune rejection.
"Calculations suggest that cells from approximately 150 selected people would provide a useful immunological match for the majority of people," said Wilmut. "We propose that an international network of stem cell banks working with common procedures and standards should be established now in order to provide the broadest range of immunological types. This would be a critical step in ensuring widespread availability of high quality cell therapies in the future."
Citation: "Toward The Development of a Global Induced Pluripotent Stem Cell Library. Turner et al.; Cell Stem Cell, October 2013, DOI: 10.1016/ j.stem. 2013.08.003
Abstract: http://dx.doi.org/10.1016/j-stem.2013.08.003 Contact: Ian Wilmut, firstname.lastname@example.org
Citation: "iPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening"; Rao et al.; Cell Stem Cell, October 2013, DOI: 10.1016/j.stem.2013.09.005
Contact: Mahendra Rao, email@example.com
Citation: "Banking Human Induced Pluripotent Stem Cells: Lessons Learned from Embryonic Stem Cells? Stacey et al. Cell Stem Cell, October 2013, DOI: 10.1016/j.stem.2013.09.007
Contact: Glyn N. Stacey, firstname.lastname@example.org
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Comment & Opinion|
|Publication:||Stem Cell Lab World|
|Date:||Oct 21, 2013|
|Previous Article:||Americord advances method of obtaining mesenchymal stem cells from placenta.|
|Next Article:||New application of TAP's ambr microscale bioreactor as perfusion mimic.|